Christopher Francis compensation by year
Wave Life Sciences Summary Compensation Table · all 6 fiscal years held| Component | FY2017 | FY2018 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $330,000 | $363,000 | $407,800 | $425,500 | $438,300 | $451,400 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $284,690 | $520,650 | $0 | $0 | $0 | $293,500 |
| Option awards | $361,194 | $668,510 | $391,305 | $871,059 | $870,312 | $1,435,451 |
| Non-equity incentive | $127,100 | $129,591 | $211,000 | $220,200 | $246,550 | $274,226 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $528 | $540 | $540 | $10,710 | $11,260 | $11,310 |
| Total | $1,103,512 | $1,682,291 | $1,010,645 | $1,527,469 | $1,566,422 | $2,465,887 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Wave Life Sciences, Inc. DEF 14A filed June 23, 2025, accession 0001193125-25-144678, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Wave Life Sciences, Inc. filed document, accession 0001193125-25-144678. Every figure is read from that document and cited to the page and table it appears in. Filed June 23, 2025.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 32,500 | $552,500 | — |
| RSU | 18,750 | $318,750 | — |
| Option | 161,100 | — | $3.87 |
| Option | 9,375 | — | $3.14 |
| Option | 76,469 | — | $4.75 |
| Option | 151,000 | — | $11.74 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Wave Life Sciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Wave Life Sciences’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Paul Bolno | President and Chief Executive Officer | $4,272,299 |
| Kyle Moran | Chief Financial Officer | $1,917,381 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $1,888,563 |
| Christopher Francis · this page | Senior Vice President, Corporate Development and Head of Emerging Areas | $1,566,422 |
Christopher Francis's compensation dossier, Wave Life Sciences
You have read Christopher Francis's totals and holdings. The dossier adds each equity grant Wave Life Sciences disclosed for Christopher Francis and Wave Life Sciences's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Wave Life Sciences compensation record
free company briefThis page is one person within Wave Life Sciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Wave Life Sciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Wave Life Sciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Wave Life Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order WVE
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.